{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:10:48Z","timestamp":1787976648580,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T00:00:00Z","timestamp":1538611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00280-018-3693-6","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T04:21:40Z","timestamp":1538626900000},"page":"1021-1029","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["A phase II study of NK012, a polymeric micelle formulation of SN-38, in unresectable, metastatic or recurrent colorectal cancer patients"],"prefix":"10.1007","volume":"82","author":[{"given":"Tetsuya","family":"Hamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uetake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taito","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Amagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,4]]},"reference":[{"key":"3693_CR1","unstructured":"Cancer Registry and Statistics Cancer information service. National Cancer Center, Japan. \n                    http:\/\/ganjoho.jp\/reg_stat\/statistics\/dl\/index.html\n                    \n                  . Accessed Aug 2016"},{"key":"3693_CR2","unstructured":"Benson AB III, Venook AP, Bekaii-Saab T et al (2016) National Comprehensive Cancer Network, Clinical Practice Guideline in Oncology (NCCN Guidelines\u00ae), Version 2.2016. NCCN.org. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp\n                    \n                  . Accessed 30 Jul 2016"},{"key":"3693_CR3","doi-asserted-by":"publisher","first-page":"12234","DOI":"10.3748\/wjg.v21.i43.12234","volume":"21","author":"K Fujita","year":"2015","unstructured":"Fujita K, Kubota Y, Ishida H, Sasaki Y (2015) Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 21:12234\u201312248","journal-title":"World J Gastroenterol"},{"key":"3693_CR4","doi-asserted-by":"publisher","first-page":"10048","DOI":"10.1158\/0008-5472.CAN-06-1605","volume":"66","author":"F Koizumi","year":"2006","unstructured":"Koizumi F, Kitagawa M, Negishi T et al (2006) Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 66:10048\u201310056","journal-title":"Cancer Res"},{"key":"3693_CR5","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1158\/0008-5472.CAN-07-6532","volume":"68","author":"M Sumitomo","year":"2008","unstructured":"Sumitomo M, Koizumi F, Asano T et al (2008) Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression. Cancer Res 68:1631\u20131635","journal-title":"Cancer Res"},{"key":"3693_CR6","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/j.1349-7006.2008.00806.x","volume":"99","author":"Y Saito","year":"2008","unstructured":"Saito Y, Yasunaga M, Kuroda J, Koga Y, Matsumura Y (2008) Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor. Cancer Sci 99:1258\u20131264","journal-title":"Cancer Sci"},{"key":"3693_CR7","doi-asserted-by":"publisher","first-page":"9318","DOI":"10.1158\/0008-5472.CAN-08-2822","volume":"68","author":"TE Nakajima","year":"2008","unstructured":"Nakajima TE, Yanagihara K, Takigahira M et al (2008) Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan. Cancer Res 68:9318\u20139322","journal-title":"Cancer Res"},{"key":"3693_CR8","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/ijc.24171","volume":"124","author":"J Kuroda","year":"2009","unstructured":"Kuroda J, Kuratsu J, Yasunaga M, Koga Y, Saito Y, Matsumura Y (2009) Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma. Int J Cancer 124:2505\u20132511","journal-title":"Int J Cancer"},{"key":"3693_CR9","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.1158\/1078-0432.CCR-08-3334","volume":"15","author":"T Nagano","year":"2009","unstructured":"Nagano T, Yasunaga M, Goto K et al (2009) Antitumor activity of NK012 combined with cisplatin against small cell lung cancer and intestinal mucosal changes in tumor-bearing mouse after treatment. Clin Cancer Res 15:4348\u20134355","journal-title":"Clin Cancer Res"},{"key":"3693_CR10","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-10-0387","volume":"16","author":"T Hamaguchi","year":"2010","unstructured":"Hamaguchi T, Doi T, Eguchi-Nakajima T et al (2010) Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin Cancer Res 16:5058\u20135066","journal-title":"Clin Cancer Res"},{"key":"3693_CR11","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s10147-008-0821-z","volume":"14","author":"M Onoue","year":"2009","unstructured":"Onoue M, Terada T, Kobayashi M et al (2009) UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 14:136\u2013142","journal-title":"Int J Clin Oncol"},{"key":"3693_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"3693_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"3693_CR14","unstructured":"National Cancer Institute (2006) Common Terminology Criteria for Adverse Events v3.0 (CTCAE). \n                    http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf\n                    \n                  . Accessed 22 Jun 2016"},{"key":"3693_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2307\/2530297","volume":"38","author":"TR Fleming","year":"1982","unstructured":"Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143\u2013151","journal-title":"Biometrics"},{"key":"3693_CR16","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","volume":"26","author":"AF Sobrero","year":"2008","unstructured":"Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311\u20132319","journal-title":"J Clin Oncol"},{"key":"3693_CR17","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1200\/JCO.1993.11.5.909","volume":"11","author":"Y Shimada","year":"1993","unstructured":"Shimada Y, Yoshino M, Wakui A et al (1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909\u2013913","journal-title":"J Clin Oncol"},{"key":"3693_CR18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00280-016-2986-x","volume":"77","author":"HA Burris","year":"2016","unstructured":"Burris HA, Infante JR, Greco FA et al (2016) A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle. Cancer Chemother Pharmacol 77:1079\u20131086","journal-title":"Cancer Chemother Pharmacol"},{"key":"3693_CR19","first-page":"423","volume":"28","author":"JG Slatter","year":"2000","unstructured":"Slatter JG, Schaaf LJ, Sams JP et al (2000) Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [14C]CPT-11 in cancer patients. Drug Metab Dispos 28:423\u2013433","journal-title":"Drug Metab Dispos"},{"key":"3693_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/sj.bjp.0703766","volume":"132","author":"C Blandizzi","year":"2001","unstructured":"Blandizzi C, De Paolis B, Colucci R, Lazzeri G, Baschiera F, Del Tacca M (2001) Characterization of a novel mechanism accounting for the adverse cholinergic effects of the anticancer drug irinotecan. Br J Pharmacol 132:73\u201384","journal-title":"Br J Pharmacol"},{"key":"3693_CR21","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.3109\/00498259109039556","volume":"21","author":"R Atsumi","year":"1991","unstructured":"Atsumi R, Suzuki W, Hakusui H (1991) Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21:1159\u20131169","journal-title":"Xenobiotica"},{"key":"3693_CR22","first-page":"3752","volume":"56","author":"K Takasuna","year":"1996","unstructured":"Takasuna K, Hagiwara T, Hirohashi M et al (1996) Involvement of \u03b2-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride. Cancer Res 56:3752\u20133757","journal-title":"Cancer Res"},{"key":"3693_CR23","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s002800050818","volume":"42","author":"K Takasuna","year":"1998","unstructured":"Takasuna K, Hagiwara T, Hirohashi M et al (1998) Inhibition of intestinal microflora \u03b2-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother Pharmacol 42:280\u2013286","journal-title":"Cancer Chemother Pharmacol"},{"key":"3693_CR24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/sj.bjc.6690364","volume":"80","author":"S Guichard","year":"1999","unstructured":"Guichard S, Terret C, Hennebelle I et al (1999) CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer 80:364\u2013370","journal-title":"Br J Cancer"},{"key":"3693_CR25","first-page":"6921","volume":"60","author":"Y Ando","year":"2000","unstructured":"Ando Y, Saka H, Ando M et al (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921\u20136926","journal-title":"Cancer Res"},{"key":"3693_CR26","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/j.1349-7006.2006.00321.x","volume":"97","author":"K Araki","year":"2006","unstructured":"Araki K, Fujita K, Ando Y et al (2006) Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 97:1255\u20131259","journal-title":"Cancer Sci"},{"key":"3693_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/FPC.0b013e328014341f","volume":"17","author":"H Minami","year":"2007","unstructured":"Minami H, Sai K, Saeki M et al (2007) Irinotecan pharmacokinetics\/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genom 17:497\u2013504","journal-title":"Pharmacogenet Genom"},{"key":"3693_CR28","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1002\/ijc.23381","volume":"122","author":"TE Nakajima","year":"2008","unstructured":"Nakajima TE, Yasunaga M, Kano Y et al (2008) Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil. Int J Cancer 122:2148\u20132153","journal-title":"Int J Cancer"},{"key":"3693_CR29","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1158\/1078-0432.CCR-09-2393","volume":"16","author":"JI Kuroda","year":"2010","unstructured":"Kuroda JI, Kuratsu JI, Yasunaga M et al (2010) Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab. Clin Cancer Res 16:521\u2013529","journal-title":"Clin Cancer Res"},{"key":"3693_CR30","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1002\/cncr.25233","volume":"116","author":"H Kenmotsu","year":"2010","unstructured":"Kenmotsu H, Yasunaga M, Goto K et al (2010) The antitumor activity of NK-012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts. Cancer 116:4597\u20134604","journal-title":"Cancer"},{"key":"3693_CR31","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1002\/ijc.25282","volume":"127","author":"T Nagano","year":"2010","unstructured":"Nagano T, Yasunaga M, Goto K et al (2010) Synergistic antitumor activity of the SN-38-incorporating polymeric micelles NK012 with S-1 in a mouse model of non-small cell lung cancer. Int J Cancer 127:2699\u20132706","journal-title":"Int J Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3693-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3693-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3693-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T23:18:20Z","timestamp":1570144700000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3693-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,4]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3693"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3693-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,4]]},"assertion":[{"value":"24 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"T. Hamaguchi has received research grants from Sumitomo Dainippon Pharma, Taiho Pharmaceutical, MSD, Teijin Pharma, Eli Lilly, Ono Pharmaceutical and Sanofi, honorariums from Novartis Pharma, Ono Pharmaceutical, Chugai Pharmaceutical, Taiho Pharmaceutical, and Yakult, and is a medical advisor for NanoCarrier. A. Tsuji has received honorariums from Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical, Merck Serono, Takeda Pharmaceutical, and Bristol-Myers Squibb, and is speaker\u2019s bureau for Chugai Pharmaceutical, Taiho Pharmaceutical, Takeda Pharmaceutical and Merck Serono. K. Yamaguchi has received speaking honorariums from Taiho Pharmaceutical, Chugai Pharmaceutical, Merck Serono, Takeda Pharmaceutical, Yakult, Bayer, Daiichi Sankyo, Ono Pharmaceutical, Eli Lilly, Sanofi, and Bristol-Myers Squibb, has received research grants from MSD, Ono Pharmaceutical, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Yakult, and has served on safety review committees for Bristol-Myers Squibb. K. Takeda has received research grants from Abbvie, Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Merck Serono, MSD, Ono Pharmaceutical, Pfizer and Taiho Pharmaceutical, and has received honorariums from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly, Kyowa Hakko Kirin, Novartis Pharma, Ono Pharmaceutical, Pfizer, and Taiho Pharmaceutical. H. Uetake has received speaking honorariums from Taiho Pharmaceutical, Chugai Pharmaceutical, Takeda Pharmaceutical, Sanofi, and Eli Lilly. T. Esaki has received honorariums from Taiho Pharmaceutical, Eli Lilly, Merck Serono, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Ono Pharmaceutical, and Daiichi Sankyo, and has received research grants from Daiichi Sankyo, MSD, Novartis Pharma, Sumitomo Dainippon Pharma, and Ono Pharmaceutical. K. Amagai has received grants from Taiho Pharmaceutical and MSD, and contributions. H. Baba has received speaking honorariums from Nippon Kayaku, Taiho Pharmaceutical, and Eli Lilly. T. Tsukamoto is an employee of Nippon Kayaku. The other authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}